Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA

Christopher D. Kosarek, Ali M. Mahmoud, Eduardo Eyzaguirre, Yong Shan, Eric Walser, Gary L. Horn, Stephen Williams

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. Patients and Methods: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. Results: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. Conclusion: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.

Original languageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Prostate
Magnetic Resonance Imaging
Biopsy
Prostatic Neoplasms
Prostate-Specific Antigen
Software

Keywords

  • Magnetic resonance imaging
  • Prostate biopsy
  • Targeted
  • Transperineal
  • UroNav

ASJC Scopus subject areas

  • Urology

Cite this

@article{2979787cbf2d4e2f8f51d67baea8af12,
title = "Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA",
abstract = "Objectives: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. Patients and Methods: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. Results: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6{\%}) were active surveillance candidates and 16 (50{\%}) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81{\%} and 59{\%}, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. Conclusion: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.",
keywords = "Magnetic resonance imaging, Prostate biopsy, Targeted, Transperineal, UroNav",
author = "Kosarek, {Christopher D.} and Mahmoud, {Ali M.} and Eduardo Eyzaguirre and Yong Shan and Eric Walser and Horn, {Gary L.} and Stephen Williams",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bju.14206",
language = "English (US)",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Initial series of magnetic resonance imaging (MRI)-fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA

AU - Kosarek, Christopher D.

AU - Mahmoud, Ali M.

AU - Eyzaguirre, Eduardo

AU - Shan, Yong

AU - Walser, Eric

AU - Horn, Gary L.

AU - Williams, Stephen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. Patients and Methods: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. Results: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. Conclusion: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.

AB - Objectives: To describe a step-by-step guide for using the first transperineal targeted prostate biopsy platform available in the USA. Patients and Methods: A total of 32 men with elevated prostate-specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications. Results: The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri-operative complications. Conclusion: These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.

KW - Magnetic resonance imaging

KW - Prostate biopsy

KW - Targeted

KW - Transperineal

KW - UroNav

UR - http://www.scopus.com/inward/record.url?scp=85045306279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045306279&partnerID=8YFLogxK

U2 - 10.1111/bju.14206

DO - 10.1111/bju.14206

M3 - Article

C2 - 29569311

AN - SCOPUS:85045306279

JO - BJU International

JF - BJU International

SN - 1464-4096

ER -